Dashboard
Manage Tickers

CC Chemours Co

NYSE chemours.com


$ 12.65 $ 0.00 (0 %)    

Monday, 10-Nov-2025 08:12:55 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 618.87 $ 0.00 (0 %)
DIA $ 471.76 $ 0.00 (0 %)
SPY $ 677.25 $ 0.00 (0 %)
TLT $ 89.29 $ 0.00 (0 %)
GLD $ 376.25 $ 0.00 (0 %)
$ 12.51
$ 11.38
$ 12.70 x 100
$ 12.88 x 463
-- - --
$ 9.08 - $ 21.71
9,955,937
na
1.88B
$ 1.72
nm
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-18-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 04-30-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 10-27-2023 09-30-2023 10-Q
10 07-28-2023 06-30-2023 10-Q
11 04-28-2023 03-31-2023 10-Q
12 02-10-2023 12-31-2022 10-K
13 10-26-2022 09-30-2022 10-Q
14 07-29-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 02-11-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 07-30-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 02-12-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-14-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-02-2019 06-30-2019 10-Q
27 05-03-2019 03-31-2019 10-Q
28 02-15-2019 12-31-2018 10-K
29 11-02-2018 09-30-2018 10-Q
30 08-03-2018 06-30-2018 10-Q
31 05-04-2018 03-31-2018 10-Q
32 02-16-2018 12-31-2017 10-K
33 11-03-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-03-2017 03-31-2017 10-Q
36 02-17-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 02-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

top-3-materials-stocks-that-are-preparing-to-pump-in-q4
Top 3 Materials Stocks That Are Preparing ...
11/07/2025 11:01:15

chemours-sees-fy2025-sales-5700b-5800b-vs-5882b-est
Chemours Sees FY2025 Sales $5.700B-$5.800B...
11/06/2025 22:57:54

Chemours (NYSE:CC) sees FY2025 sales of $5.700 billion-$5.800 billion vs $5.882 billion analyst estimate.

chemours-sees-q4-sales-1271b-1345b-vs-1394b-est
Chemours Sees Q4 Sales $1.271B-$1.345B vs ...
11/06/2025 21:40:01

chemours-q3-adj-eps-020-misses-025-estimate-sales-1495b-miss-1498b-estimate
Chemours Q3 Adj. EPS $0.20 Misses $0.25 Es...
11/06/2025 21:35:05

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

where-chemours-stands-with-analysts
Where Chemours Stands With Analysts
10/16/2025 20:00:50

mizuho-maintains-outperform-on-chemours-lowers-price-target-to-18
Mizuho Maintains Outperform on Chemours, L...
10/16/2025 13:25:42

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $19 to $18.

ubs-maintains-buy-on-chemours-raises-price-target-to-21
UBS Maintains Buy on Chemours, Raises Pric...
10/06/2025 16:27:45

UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and raises the price target from $17 to $21.

beyond-the-numbers-4-analysts-discuss-chemours-stock
Beyond The Numbers: 4 Analysts Discuss Che...
09/23/2025 19:01:41

mizuho-maintains-outperform-on-chemours-raises-price-target-to-19
Mizuho Maintains Outperform on Chemours, R...
09/23/2025 13:09:31

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $16 to $19.

truist-securities-maintains-buy-on-chemours-raises-price-target-to-21
Truist Securities Maintains Buy on Chemour...
09/16/2025 14:47:25

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the price target from $18 to $21.

agri-science-giant-corteva-eyes-breakup-to-shield-seed-unit-from-future-risks-report
Agri-Science Giant Corteva Eyes Breakup To...
09/15/2025 11:49:14

Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid f...

chemours-names-mary-cranston-board-chair-and-appoints-alister-cowan-lead-independent-director-following-dawn-farrell-departure
Chemours Names Mary Cranston Board Chair A...
09/03/2025 10:48:20

chemours-chair-dawn-farrell-resigns-effective-sept-2-to-lead-canadian-governments-new-major-projects-office
Chemours Chair Dawn Farrell Resigns Effect...
08/29/2025 20:37:02

On August 29, 2025, Dawn Farrell, Chair of the Board of Directors (the "Board") of The Chemours Company (the "Compa...

dupont-divests-aramids-business-in-18-billion-deal-to-sharpen-portfolio
DuPont Divests Aramids Business In $1.8 Bi...
08/29/2025 12:47:30

DuPont agreed to sell its Aramids business, including Kevlar and Nomex brands, to Arclin for $1.8B. Deal aligns with DuPont'...

chemours-strengthens-global-supply-chain-with-srf-limited-partnership-in-india-supporting-semiconductor-automotive-and-aerospace-applications
Chemours Strengthens Global Supply Chain W...
08/19/2025 09:36:01

samsung-electronics-qualifies-chemours-opteon-two-phase-immersion-cooling-fluid-for-gen4-ssds-advancing-ai-driven-data-center-efficiency-and-sustainability
Samsung Electronics Qualifies Chemours' Op...
08/13/2025 10:47:43

chemours-sees-q3-sales-1518b-1550b-vs-1557b-est
Chemours Sees Q3 Sales $1.518B-$1.550B vs ...
08/05/2025 21:10:32

Chemours (NYSE:CC) sees Q3 sales of $1.518 billion-$1.550 billion vs $1.557 billion analyst estimate.

chemours-sees-fy2025-sales-5900b-6000b-vs-5901b-est
Chemours Sees FY2025 Sales $5.900B-$6.000B...
08/05/2025 21:10:20

Chemours (NYSE:CC) sees FY2025 sales of $5.900 billion-$6.000 billion vs $5.901 billion analyst estimate.

chemours-q2-adj-eps-058-beats-048-estimate-sales-1615b-beat-1571b-estimate
Chemours Q2 Adj. EPS $0.58 Beats $0.48 Est...
08/05/2025 20:58:05

Chemours (NYSE:CC) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.48 by 20.83 p...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION